FindTrial
Sign In

enzastaurin hydrochloride

DRUG10 trials

Sponsors

Jonsson Comprehensive Cancer Center, Eli Lilly and Company, Gynecologic Oncology Group, Eastern Cooperative Oncology Group, Pediatric Brain Tumor Consortium

Conditions

AdultBrain and Central Nervous System TumorsBreast NeoplasmsDiffuse Large B-Cell LymphomaGlioblastomaLung CancerNeuroblastomaOvarian Cancer

Phase 1

LY317615 Plus Capecitabine in Treating Patients With Advanced Solid Tumors
CompletedNCT00052273
Jonsson Comprehensive Cancer CenterAdult, Solid Tumor
Start: 2002-12-31End: 2005-10-31Updated: 2020-08-03
Enzastaurin in Treating Young Patients With Refractory Primary CNS Tumors
CompletedNCT00503724
Pediatric Brain Tumor ConsortiumBrain and Central Nervous System Tumors, Neuroblastoma
Start: 2007-06-30End: 2010-05-31Updated: 2012-03-06
Enzastaurin and Temozolomide in Treating Patients With Primary Gliomas
NCT00516607
European Organisation for Research and Treatment of Cancer - EORTCBrain and Central Nervous System Tumors
Start: 2007-07-31Updated: 2015-02-10
Enzastaurin and Bevacizumab in Treating Patients With Locally Advanced or Metastatic Cancer
CompletedNCT00550927
Eli Lilly and CompanyUnspecified Adult Solid Tumor, Protocol Specific
Start: 2006-11-30End: 2012-09-30Target: 42Updated: 2013-05-15

Phase 2

Enzastaurin For Breast Cancer Patients Who Previously Received an Anthracycline and a Taxane Chemotherapy
CompletedNCT00386087
Eli Lilly and CompanyBreast Neoplasms
Start: 2006-11-30End: 2007-09-30Target: 41Updated: 2008-06-06
Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
CompletedNCT00407758
Gynecologic Oncology GroupOvarian Cancer, Primary Peritoneal Cavity Cancer
Start: 2006-11-30Updated: 2019-03-20
Enzastaurin, Carboplatin, and Gemcitabine With or Without Bevacizumab in Treating Patients With Recurrent, Stage IIIB, or Stage IV Non-Small Cell Lung Cancer
WithdrawnNCT00469976
Eastern Cooperative Oncology GroupLung Cancer
Start: 2007-06-30Updated: 2015-10-08
Bicalutamide With or Without Enzastaurin in Treating Patients With Prostate Cancer
WithdrawnNCT00685633
Eastern Cooperative Oncology GroupProstate Cancer
Start: 2008-12-31Updated: 2013-08-20

Phase 3

Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™
CompletedNCT03263026
Denovo Biopharma LLCDiffuse Large B-Cell Lymphoma
Start: 2018-03-20End: 2022-08-11Updated: 2025-01-23
A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1
CompletedNCT03776071
Denovo Biopharma LLCGlioblastoma
Start: 2020-12-16End: 2024-02-29Updated: 2024-04-22

Related Papers

Challenges in comparing outcomes of frontline clinical trials for diffuse large B-cell lymphoma patients selected based on the international prognostic index: A real-world analysis from the danish lymphoma registry
Blood2025-11-03
CTNI-25. CASE STUDY OF AN EXCEPTIONAL RESPONDER: ENZASTAURIN LONG TERM EFFICACY IN A PATIENT WITH PRIMARY AND RECURRENT GLIOBLASTOMA MULTIFORME (GBM)
Neuro-Oncology2021-11-021 citations
CTNI-08. DB102-01 ENGAGE STUDY: A BIOMARKER-GUIDED, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER PHASE 3 CLINICAL TRIAL OF DB102 IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
Neuro-Oncology2021-11-021 citations
ENGINE: A Phase III Randomized Placebo Controlled Study of Enzastaurin/R-CHOP as Frontline Therapy in High-Risk Diffuse Large B-Cell Lymphoma Patients with the Genomic Biomarker DGM1
Future Oncology2020-04-0620 citations
Engine: Phase III Randomized Study of Enzastaurin/R-CHOP Versus Placebo/R-CHOP in Frontline High Risk Diffuse Large B Cell Lymphoma Patients with Novel Genomic Biomarker DGM1
Blood2019-11-131 citations
PHASE III RANDOMIZED STUDY OF ENZASTAURIN/R‐CHOP VS PLACEBO/R‐CHOP IN FRONTLINE HIGH RISK DIFFUSE LARGE B CELL LYMPHOMA PATIENTS WITH GENOMIC BIOMARKER DGM1 (ENGINE STUDY)
Hematological Oncology2019-06-01
ENGINE: Phase III randomized study of enzastaurin/R-CHOP versus placebo/R-CHOP in frontline high-risk diffuse large B-cell lymphoma patients with novel genomic biomarker DGM1.
Journal of Clinical Oncology2019-05-20